J Child Neurol. 2025 Apr 15:8830738251330414. doi: 10.1177/08830738251330414. Online ahead of print.
ABSTRACT
ObjectiveThis multicenter study aimed to evaluate the efficacy and safety of oral glycopyrrolate in children with neurodisabilities experiencing moderate-to-severe drooling.MethodsA total of 159 children diagnosed with cerebral palsy, epileptic encephalopathy, or autism spectrum disorder were assessed using the Drooling Impact Scale, Drooling Severity and Frequency Scale, and quality of life measures at baseline, week 4, and week 12. A structured dose titration protocol was followed, and adverse events were systematically recorded.ResultsOf the 159 children enrolled, 130 completed the study. Significant improvements were observed in Drooling Impact Scale, Drooling Severity and Frequency Scale, and quality of life scores across all groups (P < .001). Cerebral palsy patients exhibited greater variability in Drooling Impact Scale scores than epileptic encephalopathy and autism spectrum disorder groups at weeks 4 and 12 (P < .01). Adverse effects were predominantly mild, with constipation being the most common.ConclusionGlycopyrrolate is an effective and well-tolerated treatment for drooling in children with neurodisabilities, including autism spectrum disorder and epileptic encephalopathy. It presents a viable pharmacologic option for improving salivary control and quality of life.
PMID:40232683 | DOI:10.1177/08830738251330414
